SterileAtlas Marketplaces

DiscoveryAcademic Preclinical Labs Process Dev (PDO)CDMOs

ClinicalCROs Clinical Sites Ethics / IRB Central Labs

QualityPharmacovigilance Regulatory Engineering Consultants

SupplySuppliers Equipment Packaging

DistributionLogistics Distribution Specialty Pharmacy

AccessPayers PBM

CapitalInvestors IP & Legal

SterileAtlasIntelligence Mission Control

Loading…

SterileAtlas

One marketplace for the entire drug lifecycle — global sterile pharmaceutical & biotech manufacturing intelligence.

Marketplaces

All 22 marketplaces
CDMOs
CROs
Clinical trial sites
Consultants

Opportunities

Projects, jobs & leads
Open projects
Jobs
Consulting leads

Platform

Pricing
About us
List your company
Mission Control

© 2026 SterileAtlas · Capability scores are deterministic, rules-based — not AI.

About us Terms Usage Policy Disclosures Compliance Community guidelines Privacy Cookies Refunds DPA Trust & security

Data shown across the platform is illustrative and unverified — not for vendor qualification or regulatory use.

Capital & Advisory

Investors & VC

Venture, PE & strategic capital

5

firms listed

Venture capital, private equity and strategic investors — matched to your modality, stage and geography.

SearchFaceted, over real records CompareSide-by-side scorecards Post an RFxGet qualified responses CollaborateRun it in a shared room AI assistantYour organisation, this market

Scores are deterministic, rules-based — not AI.

MarketplacesInvestors

5 firms

Sort

Mfg focus Portfolio Name

Manufacturing modality

Biologics5 Cell therapy2 Sterile injectables2 Fill-finish1 Genomic medicines1 mRNA / LNP1 Other1 Radiopharmaceuticals1 Single-use1 Small molecule1 Viral vector / AAV1

Focus & access

GMP / manufacturing focus Actively investing Accepts cold pitches Reviews inspection history

Stage

Pre-seed Seed Series A Series B Growth Crossover

Headquarters

France United States

Showing 1 of 5Clear filters Radiopharmaceuticals

New York, United States · AUM $17B

19focus

OncologyRare diseaseCardiometabolicInfectious disease

FDAEMAICH guidelines

PORT 205 companies$25M–$100M

InvestingTherapeutics-focused